Bausch & Lomb Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1992-10-08

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%

Phase 4

Completed

Conditions: Conjunctivitis, Seasonal Allergic
Conjunctivitis, Giant Papillary
Inflammation

Interventions: Drug: Prednisolone Acetate 1% Oph Susp
Drug: Loteprednol Etabonate

First Posted Date: 2011-09-21

Last Posted Date: 2019-11-19

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 140

Registration Number: NCT01437982

Locations: 🇰🇷
Bausch & Lomb Korea Ltd, Seoul, Korea, Republic of

Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)

Phase 3

Completed

Conditions: Seasonal Allergic Conjunctivitis

Interventions: Drug: Olopatadine 0.1%
Drug: Loteprednol etabonate 0.2%

First Posted Date: 2011-09-16

Last Posted Date: 2012-03-13

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 300

Registration Number: NCT01435460

Locations: 🇸🇬
Bausch & Lomb Singapore, Singapore, Singapore

Twelve Month Clinical Evaluation of KeraSoft IC Soft Contact Lenses

Not Applicable

Terminated

Conditions: Keratoconus

Interventions: Device: KeraSoft IC Soft Contact Lenses

First Posted Date: 2011-08-15

Last Posted Date: 2014-11-25

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 12

Registration Number: NCT01416272

Locations: 🇺🇸
Bausch & Lomb Incorporated, Rochester, New York, United States

A Study to Evaluate the Product Performance of the PureVision®2 High Definition (HD) Contact Lens

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: Spectacles
Device: PureVision2 HD contact lenses

First Posted Date: 2011-08-12

Last Posted Date: 2013-12-25

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 63

Registration Number: NCT01416142

Locations: 🇺🇸
Bausch & Lomb, Inc., Rochester, New York, United States

A Study to Evaluate the Product Feasibility of a New Silicone Hydrogel Contact Lens

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: Bausch & Lomb Test lens
Device: Ciba Vision soft contact lens

First Posted Date: 2011-08-09

Last Posted Date: 2014-04-29

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 100

Registration Number: NCT01412983

Locations: 🇺🇸
Bausch & Lomb Incorporated, Rochester, New York, United States

A Study to Evaluate a Modified Contact Lens

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: SofLens in currently marketed solution
Device: SofLens in investigational solution

First Posted Date: 2011-07-12

Last Posted Date: 2020-09-30

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 438

Registration Number: NCT01391364

Locations: 🇺🇸
Bausch & Lomb, Inc., Rochester, New York, United States

Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery

Phase 3

Completed

Conditions: Pain
Inflammation
Cataract

Interventions: Drug: Bromfenac Ophthalmic Solution
Drug: Placebo

First Posted Date: 2011-06-07

Last Posted Date: 2014-05-06

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 440

Registration Number: NCT01367249

Locations: 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States

Safety and Efficacy of a Contact Lens for Daily Disposable Use

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: Test, daily disposable contact lens
Device: SofLens daily disposable contact lens

First Posted Date: 2011-06-03

Last Posted Date: 2014-01-08

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 173

Registration Number: NCT01365039

Locations: 🇺🇸
Bausch & Lomb, Inc., Rochester, New York, United States

Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis

Phase 3

Terminated

Conditions: Bacterial Conjunctivitis

Interventions: Drug: Besivance
Drug: Gatifloxacin

First Posted Date: 2011-04-06

Last Posted Date: 2014-09-03

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 33

Registration Number: NCT01330355

Locations: 🇺🇸
Bausch & Lomb Incorporated, Bridgewater, New Jersey, United States

Study of A New Contact Lens Cleaning and Disinfecting Solution

Not Applicable

Completed

Conditions: Vision Disorders

Interventions: Device: Investigational Cleaning & Disinfecting Solution
Device: Clear Care Solution

First Posted Date: 2011-03-18

Last Posted Date: 2020-10-08

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 444

Registration Number: NCT01318577

Locations: 🇺🇸
Bausch & Lomb Incorporated, Rochester, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy